Age-related macular degeneration (AMD) is a leading cause of vision loss, and those over the age of 75 have a nearly 30% risk of being affected....
For patients with age-related macular degeneration (AMD), a cell therapy in development at the NYSCF Research Institute could provide what sounds like a miracle: the restoration...
The New York Stem Cell Foundation (NYSCF) today announced that they are developing a stem cell therapy to treat patients suffering from age-related macular degeneration (AMD)....
At the root of every major disease of our time is the simple question: what is going wrong with our cells? Once scientists know exactly how...
“My oldest son, Andrew, is a cancer survivor,” said Tony Coles, MD, PhD, CEO of Cerevel Therapeutics. “He was afflicted with non-Hodgkins lymphoma when he...
The Context: Age-related macular degeneration (AMD) results from the death of retinal pigmented epithelial cells (RPEs) in the eye. Bruch’s membrane is a structure that sits...
The Context: Age-related macular degeneration (AMD) is a disease which affects 8 million Americans and can lead to severe vision loss due to death of retinal...
Last week, thousands of researchers and thought leaders gathered at the annual Phacilitate Leaders World and World Stem Cell Summit in Miami to discuss recent advancements...
“Medicine shouldn’t be one size fits all,” National Institutes of Health (NIH) Director Dr. Francis Collins told the audience of the NYSCF Conference last week. “Think...
Over the past 20 years, embryonic stem cell (ESC) research has evolved from a brand new field with lots of promise to one that is actively...
Thanks to a groundbreaking new stem cell treatment, patients with age-related macular degeneration (AMD) are getting their sight back. This treatment was pioneered by the inaugural...
Leaders in stem cell biology and researchers at the forefront of translational medicine convened at the 2016 NYSCF Conference to discuss the latest advances in using...
NYSCF does not treat patients with stem cell therapies. Please visit www.clinicaltrials.gov for a complete listing of clinical trials being conducted worldwide, or consult your physician. Stem cell research...
In 2011 NYSCF awarded Dr. Pete Coffey the inaugural NYSCF–Robertson Stem Cell Prize for his pioneering work bringing stem cell therapies to patients with macular degeneration....
A team of scientists led by the NYSCF Research Institute’s Dr. Dieter Egli report the first ever patient-specific, diploid (i.e. with two sets of chromosomes, the...
Japan's regulatory body has given final go-ahead for the first-ever clinical trial testing patient-derived stem cells to treat age-related macular degeneration (AMD), a common form of...
Induced pluripotent stem (iPS) cells are slated to enter a clinical study in Japan for the treatment of age-related macular degeneration. Massayo Takahashi, an opthamologist at...
Approximately 20% of patients diagnosed with dry age-related macular degeneration develop the wet form, which leads to irreversible eye damage and eventual blindness. While the dry...
David Gamm, MD, PhD, and University of Wisconsin colleagues report the first induced pluripotent stem (iPS) cell model of Best disease, a rare, genetic disorder that...
Dieter Egli, a NYSCF Senior Research Fellow, contributed to a study published in Molecular Medicine that provides direct evidence of sight-loss recovery using induced pluripotent stem...
Dieter Egli, a NYSCF Senior Research Fellow, contributed to a study published in Molecular Medicine that provides direct evidence of sight-loss recovery using induced pluripotent stem...
The New York Stem Cell Foundation (NYSCF) announced today that Dr. Peter J. Coffey, a British stem cell scientist working to cure blindness, will be the...
Advanced Cell Technology (ACT) has developed a therapy for Stargardt’s Macular Degeneration using human embryonic stem cells. This is the second clinical trial using embryonic stem cells...
